Biovie Inc BIVI

$1.46 -0.01 (-0.68%)

Valuation

Market cap
12,764,000
Revenue TTM
$0
Net income TTM
$-22,070,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
189,800
Avg volume
5,820,362
Day's range
$1.46 – $1.52
Shares out
8,683,000
Stochastic %K
0%
Beta
0.73
Analysts
Strong Buy
Price target
$12.00

Price

Company profile

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investig...

Show more

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Industry
Biotechnology
Sector
Healthcare
Phone
775 888 3162
Website
https://bioviepharma.com
Address
680 W. Nye Lane, Suite 2014, Carson City, United States

Latest news

Stocktwits

TJ12000 Oct 2, 10:37 PM
$BIVI dumb ass gypsy named Kong
0 replies
LuckyEnzo Oct 1, 5:55 PM
@EquivalentExchange is on an absolute tear recently🔥the plays just keep getting better! If you’re not following yet you’re missing out. $BIVI $SILO $KXIN soon
0 replies
emilyparkerr Sep 30, 12:10 PM
$BIVI two positive Phase 2 datasets published: SUNRISE-PD (Parkinson's) — statistically significant motor + non-motor improvements. ADDRESS-LC (Long COVID) — statistically significant in pre-specified subgroups (~80% patients, high fatigue/PEM/cognitive impairment). Phase 3 planned for both. https://investors.bioviepharma.com/overview/default.aspx
1 replies
Itinerant Sep 29, 3:37 PM
$BIVI What is the most likely financing in this difficult situation. I suspect that it is the NIH for Long Covid.
0 replies
Rod75b15 Sep 25, 6:12 PM
$BIVI
0 replies
TJ12000 Sep 24, 1:10 PM
$BIVI skip the snake oil, buy tylenol instead.
1 replies
Itinerant Sep 23, 3:49 PM
$BIVI I think that Do is a very straightforward guy, and I like that a lot. This is a core holding for me, and I expect it to succeed greatly. JMO
1 replies
Rod75b15 Sep 21, 3:12 PM
$BIVI
0 replies